Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Beeping through chemo: can smarter alarms make infusions safer?

NCT ID NCT07718711

Knowledge-focused Sponsor: Associazione Italiana Infermieri di Area Oncologica Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 22, 2026 · Last updated Jul 23, 2026 · Updated 1 time

Summary

This observational study watches healthcare workers during routine cancer drug infusions to track how often alarms—especially air-in-line alerts—go off and how staff handle them. Researchers will measure alarm frequency, response times, and user experience with different infusion technologies. The goal is to identify safety gaps and inform better alarm design, without giving any experimental treatment.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If patterns emerge, this could point toward better alarm systems and safer infusion practices for cancer patients.
What could go wrong
This is a small observational study, not a controlled experiment, so it cannot prove that any change improves safety.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 40 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jul 2026

An estimate. Start dates often move.

Expected to finish

Jun 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Healthcare professionals involved in routine intravenous administration of antineoplastic drugs in participating oncology centres. The study will observe routine infusion procedures to evaluate infusion alarms, alarm management strategies, adherence to infusion safety practices, and user experience with infusion technologies. Infusion procedures constitute the primary unit of observation, while healthcare professionals constitute the study participants.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Healthcare professionals involved in the administration of antineoplastic drugs in participating oncology centres. * Employment in a participating study site during the study period. * Direct involvement in routine intravenous antineoplastic drug infusion procedures. * Participation in infusion procedures eligible for observation according to the study protocol. Exclusion Criteria: * Healthcare professionals not directly involved in antineoplastic drug administration. * Healthcare professionals working outside participating study sites. * Temporary staff not routinely involved in infusion activities during the observation period. * Refusal to participate in study activities where local regulations require participant notification.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Air-in-line alarm are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Air-in-line alarm Antineoplastic drug administration Infusion safety Medication safety

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    5 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • ASST Lodi

    Lodi, Lombardy, 26900, Italy

  • AUSL Parma

    Parma, Emilia-Romagna, 43126, Italy

  • Fondazione Policlinico Universitario A. Gemelli IRCCS

    Rome, Lazio, 00168, Italy

  • IEO - Istituto Europeo di Oncologia

    Milan, Lombardy, 20141, Italy

  • IRCCS Ospedale San Raffaele

    Milan, Lombardy, 20132, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.